Measuring and Understanding Market Exclusivity Length for New Prescription Drugs in France, Australia, and the USA.

Victor L Van de WieleAaron S KesselheimDeborah GleesonZhigang LuSean S TuBenjamin N Rome

Published in: Pharmaceutical medicine (2024)

Market exclusivity lengths in the USA are not longer than in France and Australia. Potential reasons include the larger US market and incentives that offer transient high generic drug prices in the USA for manufacturers that successfully challenge originator market exclusivity.

Keyphrases

health insurance
emergency department
climate change
electronic health record
antiretroviral therapy